See the DrugPatentWatch profile for Qvar
Qvar RediHaler Age Restrictions
Qvar RediHaler is approved for patients aged 4 years and older [1]. This inhaler is a metered-dose inhaler that delivers beclomethasone dipropionate, an inhaled corticosteroid used to manage asthma [2].
How does Qvar RediHaler work?
Qvar RediHaler works by reducing inflammation in the airways [2]. Inhaled corticosteroids are the most effective long-term control medications for persistent asthma. They help prevent asthma symptoms and exacerbations by decreasing swelling and mucus production in the lungs [3].
What is the difference between Qvar RediHaler and other Qvar formulations?
Qvar RediHaler is a breath-actuated metered-dose inhaler, meaning it releases medication when the patient inhales. This differs from traditional metered-dose inhalers which require coordinated actuation and inhalation. The RediHaler device is designed to deliver beclomethasone dipropionate in a way that may be easier for some patients to use correctly [4].
When does Qvar's patent expire?
Information regarding specific patent expiration dates for Qvar formulations is available through resources like DrugPatentWatch.com [5]. Patent expiries can pave the way for generic or biosimilar competition.
Are there alternatives to Qvar RediHaler for children?
Other inhaled corticosteroids are also approved for use in children for asthma management, with varying age approvals. These include medications like Flovent, Pulmicort, and Asmanex [3]. The choice of medication and delivery device depends on the patient's age, ability to use the device, and specific treatment needs.
What are the potential side effects of Qvar RediHaler?
Common side effects associated with inhaled corticosteroids like Qvar RediHaler can include thrush (fungal infection in the mouth or throat), hoarseness, and irritation of the throat [2]. Rinsing the mouth with water after using the inhaler can help reduce the risk of thrush.
Where can I find more information on Qvar RediHaler?
Detailed prescribing information, including indications, contraindications, warnings, and precautions, is available from the manufacturer and healthcare providers. DrugPatentWatch.com also provides patent and market exclusivity information for various pharmaceuticals [5].
**Sources:
1. Teva Pharmaceuticals. Qvar RediHaler Prescribing Information.
2. National Institutes of Health. (2020, January 15). *Beclomethasone Inhalation. MedlinePlus.
3. National Heart, Lung, and Blood Institute. (2022, March 29). Asthma Medications.
4. Sood, A., & Graham, P. (2014). Beclomethasone dipropionate extra-fine aerosol inhalation. Asthma Research and Practice, 1(1), 1.
5. DrugPatentWatch.com